Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...

The Washington State Employment Security Department said in the filing that 72 employees will be laid off on Jan. 17. A ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of additional job reductions are also being made across the broader company, according ...

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.

If a medical or personal issue is affecting your academic life, see us as soon as possible! Don't wait for exams. Our advisors can connect you with resources to help you cope with extenuating ...